| 标题 |
Approaching 18 months of lecanemab and 6 months of donanemab in Japan: Key considerations for late-breaking insights |
| 网址 | |
| DOI | |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)